Opportunities span targeted biologics, oral inhibitors, CAR-T and other cell therapies, precision diagnostics, and self-administered delivery. High unmet need, limited approved options, strong pipelines, and partnerships offer openings, especially in Europe and Asia-Pacific.
Systemic Lupus Erythematosus Market
Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) — The “Systemic Lupus Erythematosus Market by Type of Molecule, Drug Class, Route of Administration, Type of Therapy, Geographical Regions and Sales Forecast – Trends and Forecast, Till 2035” has been added to ResearchAndMarkets.com’s offering.
Systemic Lupus Erythematosus Market to Reach USD 6.54 Billion by 2035, Growing at an 11.4% CAGR
The global systemic lupus erythematosus market is estimated to increase from USD 2.47 billion in 2026 to approximately USD 6.54 billion by 2035, representing a compound annual growth rate of 11.4%. Market expansion is being supported by the rising adoption of targeted biologics, continued investment in drug development, advances in precision diagnostics and an expanding clinical pipeline.
Systemic lupus erythematosus remains a significant area of unmet need within the autoimmune disease sector because of its clinical heterogeneity, multi-organ involvement and variable treatment response. The condition can affect the skin, joints, kidneys, central nervous system and cardiovascular system. Approximately 3.6 million people worldwide are estimated to have systemic lupus erythematosus, with a reported global prevalence of nearly 43.7 cases per 100,000 people. Disease onset occurs most frequently between 15 and 44 years of age, while adult women are disproportionately affected.
Targeted Biologics and Pipeline Innovation Drive Market Growth
The systemic lupus erythematosus treatment market is shifting from conventional corticosteroids, antimalarials and immunosuppressants toward targeted biologics, monoclonal antibodies, B-cell inhibitors, oral small molecules and cell-based therapies. Long-term safety concerns associated with conventional treatment regimens have increased demand for therapies that can reduce disease activity, limit organ damage and lower corticosteroid dependence.
Benlysta, developed by GSK, and Saphnelo, developed by AstraZeneca, have achieved strong clinical and commercial adoption, collectively generating approximately USD 2.7 billion in sales. Drug-delivery innovation is also improving treatment convenience. In December 2025, the European Union approved a subcutaneous, self-administered formulation of Saphnelo, expanding administration options for patients receiving standard-of-care therapy.
The late-stage systemic lupus erythematosus pipeline includes candidates such as deucravacitinib from Bristol Myers Squibb, litifilimab from Biogen and upadacitinib from AbbVie. These programs are evaluating novel mechanisms intended to address persistent therapeutic gaps and improve outcomes across diverse patient populations. Strategic financing is further accelerating development, as demonstrated by Royalty Pharma’s USD 250 million research and development investment supporting Biogen’s litifilimab program.
Clinical Development Landscape
More than 130 systemic lupus erythematosus therapies are approved or under investigation, with approximately 96% progressing through clinical development. Cell therapies account for about 42% of the identified pipeline, and CAR-T therapies represent nearly 83% of that category. These candidates are being evaluated as monotherapies and combination treatments across multiple development stages.
Approximately 25,000 patients have been enrolled in clinical trials evaluating systemic lupus erythematosus therapies, including nearly 10,000 participants enrolled during the past two years. More than 45% of therapy developers are headquartered in Asia-Pacific and other emerging regions, with China and Japan becoming important centers for autoimmune drug research and development.
Despite substantial innovation, drug development remains challenging. More than 30 systemic lupus erythematosus therapies have been discontinued, with nearly 55% of discontinued candidates failing during Phase II trials. Approximately 35% were discontinued after failing to meet primary clinical endpoints. Disease heterogeneity, high placebo response rates, endpoint selection and trial-design limitations continue to affect clinical success.
Diagnosis also remains a major barrier to market development and timely treatment. Patients may experience an average delay of nearly seven years before receiving an accurate diagnosis, increasing the risk of irreversible organ damage and reducing opportunities for earlier therapeutic intervention.
Regional and Segment Outlook
North America is expected to account for more than 80% of the global systemic lupus erythematosus market in 2026. Its leading position is supported by disease prevalence, rapid adoption of targeted therapies, established healthcare infrastructure and favorable reimbursement pathways. Europe is projected to record faster growth, with an estimated CAGR of 20.8% through 2035, driven by anticipated product approvals and broader access to advanced treatments.
Monoclonal antibodies are expected to represent approximately 95% of the market in 2026, supported by the established use and continued label expansion of Benlysta and Saphnelo. The inhibitors segment is forecast to grow more rapidly as oral candidates such as cenerimod, deucravacitinib and upadacitinib advance toward potential commercialization.
Intravenous therapies are projected to account for nearly 70% of the market in 2026 because of the administration profile of approved and near-term pipeline products. Oral therapies, however, are forecast to achieve the fastest growth, with a projected CAGR of 47.3%, reflecting demand for non-invasive administration and improved treatment adherence.
Systemic Lupus Erythematosus Market Segmentation
- By molecule type: Biologics and small molecules
- By drug class: Monoclonal antibodies, fusion proteins, inhibitors and immunomodulators
- By route of administration: Intravenous, subcutaneous and oral
- By therapy type: Monotherapies and combination therapies
- By region: North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America
Leading Systemic Lupus Erythematosus Companies
Prominent companies active in the systemic lupus erythematosus therapeutics market include AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Novartis, Pfizer, Roche and Sanofi. Competition is expected to intensify as established pharmaceutical companies and emerging biotechnology developers pursue differentiated biologics, immunomodulators, small molecules and cell therapies.
Report Coverage and Strategic Value
The market report provides revenue forecasts and opportunity assessments by molecule type, drug class, route of administration, therapy type and geography. It also examines the systemic lupus erythematosus therapy pipeline, start-up ecosystem, clinical trial activity, discontinued drug programs, competitive landscape and profiles of leading companies across North America, Europe and Asia-Pacific.
The analysis addresses key market drivers, barriers, emerging opportunities and development challenges. It is designed to help pharmaceutical companies, biotechnology firms, investors, healthcare organizations and other stakeholders evaluate market potential, identify high-growth segments, assess competitive positioning and support evidence-based business strategies.
Additional report benefits include a presentation-based insights pack, Excel data packs covering analytical modules, up to 15% content customization, a report walkthrough with the research team and a complimentary update for reports that are more than six months old.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 173 |
| Forecast Period | 2026 – 2035 |
| Estimated Market Value (USD) in 2026 | $2.47 Billion |
| Forecasted Market Value (USD) by 2035 | $6.54 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
Key Topics Covered:
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. An Overview of Systemic Lupus Erythematosus
6.2. Pathogenesis of Systemic Lupus Erythematosus
6.3. Symptoms of Systemic Lupus Erythematosus
6.4. Global Statistics of Systemic Lupus Erythematosus
6.5. Treatment Guidelines for Systemic Lupus Erythematosus
6.6. Diagnosis of Systemic Lupus Erythematosus
6.7. Future Perspectives
7. MARKET LANDSCAPE OF SYSTEMIC LUPUS ERYTHEMATOSUS THERAPIES
7.1. Methodology and Key Parameters
7.2. Systemic Lupus Erythematosus Therapies: Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Drug Class
7.2.3. Analysis by Type of Molecule
7.2.4. Analysis by Type of Therapy
7.2.5. Analysis by Therapy Role
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Drug Frequency
7.2.8. Analysis by Patient Type
7.2.9. Analysis by Year of Establishment
7.2.10. Analysis by Company Size
7.2.11. Analysis by Location of Headquarters
8. STARTUP ECOSYSTEM ANALYSIS
8.1. Methodology and Key Parameters
8.2. Systemic Lupus Erythematosus Therapies: Startup Ecosystem Analysis
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Type of Molecule
8.2.3. Analysis by Drug Class
8.2.4. Analysis by Type of Therapy
8.2.5. Analysis by Route of Administration
8.2.6. Analysis by Year of Establishment
8.2.7. Analysis by Company Size
8.2.8. Analysis by Location of Headquarters
9. COMPANY PROFILES
9.1. Overview
9.2. Leading Systemic Lupus Erythematosus Therapy Developers
9.2.1. AbbVie
9.2.1.1. Company Overview
9.2.1.2. Business Segments
9.2.1.3. SLE Therapies Portfolio
9.2.1.4. Key Initiatives
9.2.2. Amgen
9.2.3. AstraZeneca
9.2.4. Bristol-Myers Squibb
9.2.5. GSK
9.2.6. Novartis
9.2.7. Pfizer
9.2.8. Roche
9.2.9. Sanofi
10. CLINICAL TRIAL ANALYSIS
10.1. Methodology and Key Parameters
10.2. Systemic Lupus Erythematosus Therapies: Clinical Trial Analysis
10.2.1. Analysis by Trial Registration Year
10.2.2. Analysis by Trial Status
10.2.3. Analysis by Trial Registration Year and Trial Status
10.2.4. Analysis by Trial Registration Year and Patients Enrolled
10.2.5. Analysis by Trial Phase
10.2.6. Analysis by Trial Registration Year and Trial Phase
10.2.7. Analysis of Patients Enrolled by Trial Phase
10.2.8. Analysis by Patient Gender
10.2.9. Analysis by Study Design
10.2.9.1. Analysis by Design Masking
10.2.9.2. Analysis by Intervention Model
10.2.9.3. Analysis by Trial Purpose
10.2.9.4. Analysis by Allocation
10.2.10. Analysis by Target Patient Population
10.2.11. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
10.2.11.1. Analysis by Leading Industry Players
10.2.11.2. Analysis by Leading Non-Industry Players
10.2.13. Analysis by Geography
10.2.13.1. Analysis of Clinical Trials by Trial Status and Geography
10.2.13.2. Analysis of Patients Enrolled by Trial Status and Geography
11. DRUG FAILURE ANALYSIS
11.1. Methodology and Key Parameters
11.2. Systemic Lupus Erythematosus Therapies: Drug Failure Analysis
11.2.1. Analysis by Trial Phase
11.2.2. Analysis by Trial Status
11.2.3. Analysis by Reason of Drug Discontinuation
11.2.4. Analysis by Study Start Year and Year of Discontinuation
11.2.5. Analysis by Type of Molecule and Drug Class
11.2.6. Analysis by Type of Therapy
11.2.7. Analysis by Route of Administration
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Market Drivers
12.2. Market Restraints
12.3. Market Opportunities
12.4. Market Challenges
13. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET
13.1. Key Assumptions and Methodology
13.2. Global Systemic Lupus Erythematosus Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
13.2.1. Multivariate Scenario Analysis
13.2.1.1. Conservative Scenario
13.2.1.2. Optimistic Scenario
13.3. Key Market Segmentations
14. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY TYPE OF MOLECULE
14.1. Key Assumptions and Methodology
14.2. Systemic Lupus Erythematosus Market: Distribution by Type of Molecule
14.2.1. Systemic Lupus Erythematosus Market for Biologics, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
14.2.2. Systemic Lupus Erythematosus Market for Small Molecules, Forecasted Estimates (till 2035)
14.3. Data Triangulation and Validation
15. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY DRUG CLASS
15.1. Key Assumptions and Methodology
15.2. Systemic Lupus Erythematosus Market: Distribution by Drug Class
15.2.1. Systemic Lupus Erythematosus Market for Monoclonal Antibodies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
15.2.2. Systemic Lupus Erythematosus Market for Fusion Proteins, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
15.2.3. Systemic Lupus Erythematosus Market for Inhibitors, Forecasted Estimates (till 2035)
15.2.4. Systemic Lupus Erythematosus Market for Immunomodulators, Forecasted Estimates (till 2035)
15.3. Data Triangulation and Validation
16. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY ROUTE OF ADMINISTRATION
16.1. Key Assumptions and Methodology
16.2. Systemic Lupus Erythematosus Market: Distribution by Route of Administration
16.2.1. Systemic Lupus Erythematosus Market for Intravenous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
16.2.2. Systemic Lupus Erythematosus Market for Subcutaneous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
16.2.3. Systemic Lupus Erythematosus Market for Oral Route, Forecasted Estimates (till 2035)
16.3. Data Triangulation and Validation
17. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY TYPE of THERAPY
17.1. Key Assumptions and Methodology
17.2. Systemic Lupus Erythematosus Market: Distribution by Type of Therapy
17.2.1. Systemic Lupus Erythematosus Market for Monotherapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
17.2.2. Systemic Lupus Erythematosus Market for Combination Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
17.3. Data Triangulation and Validation
18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY GEOGRAPHICAL REGIONS
18.1. Key Assumptions and Methodology
18.2. Systemic Lupus Erythematosus Market: Distribution by Geographical Regions
18.2.1. Systemic Lupus Erythematosus Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.1.1. Systemic Lupus Erythematosus Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.1.2. Systemic Lupus Erythematosus Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2. Systemic Lupus Erythematosus Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.1. Systemic Lupus Erythematosus Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.2. Systemic Lupus Erythematosus Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.3. Systemic Lupus Erythematosus Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.4. Systemic Lupus Erythematosus Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.5. Systemic Lupus Erythematosus Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.2.6. Systemic Lupus Erythematosus Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.3. Systemic Lupus Erythematosus Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.3.1. Systemic Lupus Erythematosus Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.3.2. Systemic Lupus Erythematosus Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.3.3. Systemic Lupus Erythematosus Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.3.4. Systemic Lupus Erythematosus Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.4. Systemic Lupus Erythematosus Market in Middle East and North Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.4.1. Systemic Lupus Erythematosus Market in Saudi Arabia, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.4.2. Systemic Lupus Erythematosus Market in the UAE, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.5. Systemic Lupus Erythematosus Market in Latin America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.5.1. Systemic Lupus Erythematosus Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.2.5.2. Systemic Lupus Erythematosus Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, SALES FORECAST
19.1. Key Assumptions and Methodology
19.2. Systemic Lupus Erythematosus Market: Sales Forecast
19.2.1. Systemic Lupus Erythematosus Market for Benlysta, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.2.2. Systemic Lupus Erythematosus Market for Saphnelo Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.2.3. Systemic Lupus Erythematosus Market for Telitacicept, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.2.4. Systemic Lupus Erythematosus Market for Dapirolizumab Pegol, Forecasted Estimates (till 2035)
19.2.5. Systemic Lupus Erythematosus Market for Obinutuzumab, Forecasted Estimates (till 2035)
19.2.6. Systemic Lupus Erythematosus Market for Litifilimab, Forecasted Estimates (till 2035)
19.2.7. Systemic Lupus Erythematosus Market for Cenerimod Forecasted Estimates (till 2035)
19.2.8. Systemic Lupus Erythematosus Market for Deucravacitinib, Forecasted Estimates (till 2035)
19.2.9. Systemic Lupus Erythematosus Market for Upadacitinib, Forecasted Estimates (till 2035)
19.2.10. Systemic Lupus Erythematosus Market for Ianalumab, Forecasted Estimates (till 2035)
19.3. Data Triangulation and Validation
20. CONCLUDING INSIGHTS
21. TABULATED DATA
22. LIST OF COMPANIES AND ORGANIZATIONS
List of Tables
Table 7.1 Systemic Lupus Erythematosus Therapies: List of Systemic Lupus Erythematosus Therapies
Table 7.2 Systemic Lupus Erythematosus Therapy Developers: List of Systemic Lupus Erythematosus Therapy Developers
Table 8.1 Startup Ecosystem Analysis: List of Systemic Lupus Erythematosus Therapies Developed by Startups
Table 8.2 Startup Ecosystem Analysis Therapy Developers: List of Systemic Lupus Erythematosus Therapy Startups
Table 10.1 Systemic Lupus Erythematosus Therapies: List of Clinical Trials, 2021-2025
Table 11.1 Systemic Lupus Erythematosus Therapies: List of Discontinued Systemic Lupus Erythematosus Therapies
Table 13.1 Global Systemic Lupus Erythematosus Market: List of Systemic Lupus Erythematosus Therapies Forecasted
Table 21.1 System Lupus Erythematosus Therapies: Distribution by Stage of Development
Table 21.2 System Lupus Erythematosus Therapies: Distribution by Drug Class
Table 21.3 System Lupus Erythematosus Therapies: Distribution by Type of Molecule
Table 21.4 System Lupus Erythematosus Therapies: Distribution by Type of Therapy
Table 21.5 System Lupus Erythematosus Therapies: Distribution by Therapy Role
Table 21.6 System Lupus Erythematosus Therapies: Distribution by Route of Administration
Table 21.7 System Lupus Erythematosus Therapies: Distribution by Drug Frequency
Table 21.8 System Lupus Erythematosus Therapies: Distribution by Patient Type
Table 21.9 System Lupus Erythematosus Therapy Developers: Distribution by Year of Establishment
Table 21.10 System Lupus Erythematosus Therapy Developers: Distribution by Company Size
Table 21.11 System Lupus Erythematosus Therapy Developers: Distribution by Location of Headquarters
Table 21.12 Startup Ecosystem Analysis: Distribution by Stage of Development
Table 21.13 Startup Ecosystem Analysis: Distribution by Type of Molecule
Table 21.14 Startup Ecosystem Analysis: Distribution by Drug Class
Table 21.15 Startup Ecosystem Analysis: Distribution by Type of Therapy
Table 21.16 Startup Ecosystem Analysis: Distribution by Route of Administration
Table 21.17 Startup Ecosystem Analysis: Distribution by Year of Establishment
Table 21.18 Startup Ecosystem Analysis: Distribution by Company Size
Table 21.19 Startup Ecosystem Analysis: Distribution by Location of Headquarters
Table 21.20 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 21.21 Clinical Trial Analysis: Distribution by Trial Status
Table 21.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 21.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 21.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 21.25 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 21.26 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Table 21.27 Clinical Trial Analysis: Distribution by Patient Gender
Table 21.28 Clinical Trial Analysis: Distribution by Design Masking
Table 21.29 Clinical Trial Analysis: Distribution by Intervention Model
Table 21.30 Clinical Trial Analysis: Distribution by Trial Purpose
Table 21.31 Clinical Trial Analysis: Distribution by Allocation
Table 21.32 Clinical Trial Analysis: Distribution by Target Patient Population
Table 21.33 Most Active Industry Players: Distribution by Number of Clinical Trials
Table 21.34 Most Active Non-Industry Players: Distribution by Number of Clinical Trials
Table 21.35 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 21.36 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 21.37 Drug Failure Analysis: Distribution by Phase of Discontinuation
Table 21.38 Drug Failure Analysis: Distribution by Status of Discontinuation
Table 21.39 Drug Failure Analysis: Distribution by Reason of Drug Discontinuation
Table 21.40 Drug Failure Analysis: Distribution by Study Start Year and Year of Discontinuation
Table 21.41 Drug Failure Analysis: Distribution by Type of Molecule and Drug Class
Table 21.42 Drug Failure Analysis: Distribution by Type of Therapy
Table 21.43 Drug Failure Analysis: Distribution by Route of Administration
Table 21.44 Global Systemic Lupus Erythematosus Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.45 Systemic Lupus Erythematosus Market: Distribution by Type of Molecule
Table 21.46 Systemic Lupus Erythematosus Market for Biologics, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.47 Systemic Lupus Erythematosus Market for Small Molecules, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.48 Systemic Lupus Erythematosus Market: Distribution by Drug Class,
Table 21.49 Systemic Lupus Erythematosus Market for Monoclonal Antibodies, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.50 Systemic Lupus Erythematosus Market for Fusion Proteins, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.51 Systemic Lupus Erythematosus Market for Inhibitors, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.52 Systemic Lupus Erythematosus Market for Immunomodulators, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.53 Systemic Lupus Erythematosus Market: Distribution by Route of Administration
Table 21.54 Systemic Lupus Erythematosus Market for Intravenous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.55 Systemic Lupus Erythematosus Market for Subcutaneous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.56 Systemic Lupus Erythematosus Market for Oral Route, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.57 Systemic Lupus Erythematosus Market: Distribution by Type of Therapy
Table 21.58 Systemic Lupus Erythematosus Market for Monotherapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.59 Systemic Lupus Erythematosus Market for Combination Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.60 Systemic Lupus Erythematosus Market: Distribution by Geographical Regions
Table 21.61 Systemic Lupus Erythematosus Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.62 Systemic Lupus Erythematosus Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.63 Systemic Lupus Erythematosus Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.64 Systemic Lupus Erythematosus Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.65 Systemic Lupus Erythematosus Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.66 Systemic Lupus Erythematosus Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.67 Systemic Lupus Erythematosus Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.68 Systemic Lupus Erythematosus Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.69 Systemic Lupus Erythematosus Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.70 Systemic Lupus Erythematosus Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.71 Systemic Lupus Erythematosus Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.72 Systemic Lupus Erythematosus Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.73 Systemic Lupus Erythematosus Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.74 Systemic Lupus Erythematosus Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.75 Systemic Lupus Erythematosus Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.76 Systemic Lupus Erythematosus Market in Middle East and North Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.77 Systemic Lupus Erythematosus Market in Saudi Arabia, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.78 Systemic Lupus Erythematosus Market in UAE, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.79 Systemic Lupus Erythematosus Market in Latin America, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.80 Systemic Lupus Erythematosus Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.81 Systemic Lupus Erythematosus Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.82 Systemic Lupus Erythematosus Market for Benlysta, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.83 Systemic Lupus Erythematosus Market for Saphnelo, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.84 Systemic Lupus Erythematosus Market for Telitacicept, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.85 Systemic Lupus Erythematosus Market for Dapirolizumab Pegol, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.86 Systemic Lupus Erythematosus Market for Obinutuzumab, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.87 Systemic Lupus Erythematosus Market for Litifilimab, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.88 Systemic Lupus Erythematosus Market for Cenerimod, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.89 Systemic Lupus Erythematosus Market for Deucravacitinib, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.90 Systemic Lupus Erythematosus Market for Upadacitinib, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
Table 21.91 Systemic Lupus Erythematosus Market for Ianalumab, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenario (USD Million)
List of Figures
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Pathogenesis of Systemic Lupus Erythematosus
Figure 6.2 Global Statistics of Systemic Lupus Erythematosus
Figure 6.3 Diagnosis of Systemic Lupus Erythematosus
Figure 6.4 Future Perspectives
Figure 7.1 Systemic Lupus Erythematosus Therapies: Distribution by Stage of Development
Figure 7.2 Systemic Lupus Erythematosus Therapies: Distribution by Drug Class
Figure 7.3 Systemic Lupus Erythematosus Therapies: Distribution by Type of Molecule
Figure 7.4 Systemic Lupus Erythematosus Therapies: Distribution by Type of Therapy
Figure 7.5 Systemic Lupus Erythematosus Therapies: Distribution by Therapy Role
Figure 7.6 Systemic Lupus Erythematosus Therapies: Distribution by Route of Administration
Figure 7.7 Systemic Lupus Erythematosus Therapies: Distribution by Drug Frequency
Figure 7.8 Systemic Lupus Erythematosus Therapies: Distribution by Patient Type
Figure 7.9 Systemic Lupus Erythematosus Therapy Developers: Distribution by Year of Establishment
Figure 7.10 Systemic Lupus Erythematosus Therapy Developers: Distribution by Company Size
Figure 7.11 Systemic Lupus Erythematosus Therapy Developers: Distribution by Location of Headquarters
Figure 8.1 Startup Ecosystem Analysis: Distribution by Stage of Development
Figure 8.2 Startup Ecosystem Analysis: Distribution by Type of Molecule
Figure 8.3 Startup Ecosystem Analysis: Distribution by Drug Class
Figure 8.4 Startup Ecosystem Analysis: Distribution by Type of Therapy
Figure 8.5 Startup Ecosystem Analysis: Distribution by Route of Administration
Figure 8.6 Startup Ecosystem Analysis: Distribution by Year of Establishment
Figure 8.7 Startup Ecosystem Analysis: Distribution by Company Size
Figure 8.8 Startup Ecosystem Analysis: Distribution by Location of Headquarters
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 10.7 Clinical Trial Analysis: Distribution by Patients Enrolled by Trial Phase
Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.10 Clinical Trial Analysis: Distribution by Design Masking
Figure 10.11 Clinical Trial Analysis: Distribution by Intervention Model
Figure 10.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.13 Clinical Trial Analysis: Distribution by Allocation
Figure 10.14 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 10.15 Most Active Industry Players: Distribution by Number of Clinical Trials
Figure 10.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials
Figure 10.17 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 10.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 11.1 Drug Failure Analysis: Distribution by Trial Phase
Figure 11.2 Drug Failure Analysis: Distribution by Trial Status
Figure 11.3 Drug Failure Analysis: Distribution by Reason of Drug Discontinuation
Figure 11.4 Drug Failure Analysis: Distribution by Study Start Year and Year of Discontinuation
Figure 11.5 Drug Failure Analysis: Distribution by Type of Therapy
Figure 11.6 Drug Failure Analysis: Distribution by Route of Administration
Figure 13.1 Global Systemic Lupus Erythematosus Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 13.2 Global Systemic Lupus Erythematosus Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 13.3 Global Systemic Lupus Erythematosus Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 14.1 Systemic Lupus Erythematosus Market for Biologics, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 14.2 Systemic Lupus Erythematosus Market for Small Molecules, Forecasted Estimates (till 2035) (USD Million)
Figure 15.1 Systemic Lupus Erythematosus Market for Monoclonal Antibodies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 15.2 Systemic Lupus Erythematosus Market for Fusion Proteins, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 15.3 Systemic Lupus Erythematosus Market for Inhibitors, Forecasted Estimates (till 2035) (USD Million)
Figure 15.4 Systemic Lupus Erythematosus Market for Immunomodulators, Forecasted Estimates (till 2035) (USD Million)
Figure 16.1 Systemic Lupus Erythematosus Market for Intravenous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 16.2 Systemic Lupus Erythematosus Market for Subcutaneous Route, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 16.3 Systemic Lupus Erythematosus Market for Oral Route, Forecasted Estimates (till 2035) (USD Million)
Figure 17.1 Systemic Lupus Erythematosus Market for Monotherapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.2 Systemic Lupus Erythematosus Market for Combination Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.1 Systemic Lupus Erythematosus Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.2 Systemic Lupus Erythematosus Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Systemic Lupus Erythematosus Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.4 Systemic Lupus Erythematosus Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.5 Systemic Lupus Erythematosus Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.6 Systemic Lupus Erythematosus Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.7 Systemic Lupus Erythematosus Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.8 Systemic Lupus Erythematosus Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.9 Systemic Lupus Erythematosus Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.10 Systemic Lupus Erythematosus Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.11 Systemic Lupus Erythematosus Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.12 Systemic Lupus Erythematosus Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.13 Systemic Lupus Erythematosus Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.14 Systemic Lupus Erythematosus Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.15 Systemic Lupus Erythematosus Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.16 Systemic Lupus Erythematosus Market in Middle East and North Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.17 Systemic Lupus Erythematosus Market in Saudi Arabia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.18 Systemic Lupus Erythematosus Market in UAE, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.19 Systemic Lupus Erythematosus Market in Latin America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.20 Systemic Lupus Erythematosus Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.21 Systemic Lupus Erythematosus Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 Systemic Lupus Erythematosus Market for Benlysta, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.2 Systemic Lupus Erythematosus Market for Saphnelo, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Systemic Lupus Erythematosus Market for Telitacicept, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Systemic Lupus Erythematosus Market for Dapirolizumab Pegol, Forecasted Estimates (till 2035) (USD Million)
Figure 19.5 Systemic Lupus Erythematosus Market for Obinutuzumab, Forecasted Estimates (till 2035) (USD Million)
Figure 19.6 Systemic Lupus Erythematosus Market for Litifilimab, Forecasted Estimates (till 2035) (USD Million)
Figure 19.7 Systemic Lupus Erythematosus Market for Cenerimod, Forecasted Estimates (till 2035) (USD Million)
Figure 19.8 Systemic Lupus Erythematosus Market for Deucravacitinib, Forecasted Estimates (till 2035) (USD Million)
Figure 19.9 Systemic Lupus Erythematosus Market for Upadacitinib, Forecasted Estimates (till 2035) (USD Million)
Figure 19.10 Systemic Lupus Erythematosus Market for Ianalumab, Forecasted Estimates (till 2035) (USD Million)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- AbelZeta Pharma
- Ablynx (a subsidiary of Sanofi)
- Adicet Bio
- Allogene Therapeutics
- Alpine Immune Sciences (a subsidiary of Vertex)
- Alumis
- Amgen
- Anthera Pharmaceuticals
- Argos Therapeutics
- Artiva Biotherapeutics
- Asahi Kasei
- Ascentage Pharma
- AstraZeneca
- Atara Biotherapeutics
- Athos Therapeutics
- Autolus Therapeutics
- Baili-Bio (Chengdu) Pharmaceutical
- Beijing GoBroad Hospital
- Beijing Immunochina Medical Science & Technology
- Beijing Mabworks Biotech
- Beijing Shenzhou Cell Biotechnology
- Beike Biotechnology
- BIOCAD
- Biocon
- Biogen
- Bristol-Myers Squibb
- Cabaletta Bio
- Calibr (a subsidiary of Scripps Research)
- Candid Therapeutics
- CARsgen Therapeutics
- Cartesian Therapeutics
- CDT Equity (formerly known as Conduit Pharmaceuticals)
- Celgene (a subsidiary of Bristol-Myers Squibb)
- Century Therapeutics
- Changhai Hospital
- Chia Tai Tianqing Pharmaceutical
- Children’s Hospital Zhejiang University School of Medicine
- China Immunotech (Beijing) Biotechnology
- Chongqing Precision Biotech
- Climb Bio
- CorestemChemon
- CRISPR Therapeutics
- CSPC Pharmaceutical
- Cugene
- Cullinan Therapeutics
- CytoCares
- Daiichi Sankyo
- DualityBio
- EdiGene
- Eisai
- Eli Lilly
- EMD Serono (a subsidiary of Merck KGaA)
- Equillium
- Essen BioTech
- Excyte Biopharma
- Fate Therapeutics
- First Affiliated Hospital of Wenzhou Medical University
- Fortrea
- Galapagos
- Galilee Clinical Bio Research
- Genentech
- Genrix Bio
- Gracell Biotechnologies
- GSK
- Guangdong Ruishun Biotech
- Guangzhou Bio-gene Technology
- Hangzhou Sumgen Biotech
- Hanyang University Seoul Hospital
- HC Biopharma
- Hengrui Pharma
- Huazhong University of Science and Technology
- IASO Bio
- iCAR Bio Therapeutics
- iCell Gene Therapeutics
- IGM Biosciences
- ImmuneOnco Biopharmaceuticals
- Imviva Biotech
- Incyte
- InnoCare Pharma
- Institute of Hematology and Blood Diseases Hospital
- IQVIA
- ITabMed
- Janssen Research & Development (a subsidiary of J&J)
- Jemincare
- Jiangsu ZuoYou Medicine
- Johnson & Johnson
- Juno Therapeutics (a subsidiary of Bristol-Myers Squibb)
- Juventas Cell Therapy
- JW Therapeutics
- Kangpu Biopharmaceuticals
- Keymed Biosciences
- Kezar Life Sciences
- Kira Pharmacenticals
- Kite Therapeutics (a subsidiary of Gilead Sciences)
- Kunming Pharmaceuticals
- Kyowa Kirin
- Kyverna Therapeutics
- La Jolla Pharmaceutical
- Leman Biotech
- LiveKidney.Bio
- Luminary Therapeutics
- Lyell Immunopharma
- Mallinckrodt Pharmaceuticals
- Medical University of South Carolina
- Merck KGaA
- Millennium Pharmaceuticals
- Miltenyi Biomedicine
- Mitsubishi Tanabe Pharma
- Nanjing Drum Tower Hospital
- Nanjing Legend Biotech
- Nektar Therapeutics
- Neutrolis
- Novartis
- Otsuka Pharmaceutical
- Peking Union Medical College Hospital
- Peking University People’s Hospital
- PersonGen BioTherapeutics
- Pfizer
- PPD
- Provention Bio (a subsidiary of Sanofi)
- Qilu Pharmaceutical
- Qyuns Therapeutics
- RemeGen
- RenJi Hospital
- Resolve Therapeutics
- Roche
- Rui Therapeutics
- Sana Biotechnology
- Sanofi
- SBI Biotech
- Shanghai Cell Therapy
- Shanghai First Song Therapeutics
- Shanghai Ming Ju Biotechnology
- Shanghai Simnova Biotechnology
- Shanghai Xiniao Biotech
- Sichuan Biokin Pharmaceutical
- Sunshine Guojian Pharmaceutical
- Suzhou Yasheng Pharmaceutical
- Synthekine
- Takeda
- Teva Pharmaceutical
- The First Affiliated Hospital of Henan University
- The First Affiliated Hospital with Nanjing Medical University
- Timberlyne Therapeutics
- TJ Biopharma
- Tongji Medical College
- UCB Biopharma
- Viatris
- Zenas BioPharma
- Zhejiang University
For more information about this report visit https://www.researchandmarkets.com/r/lf5nrt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Systemic Lupus Erythematosus Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
